These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22553309)

  • 21. Detemir vs Glargine: Comparison of Inpatient Glycemic Control.
    Capson J; Cade K; Avanesyan A
    J Am Osteopath Assoc; 2019 Feb; 119(2):89-95. PubMed ID: 30688354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: A systematic review and meta-analysis.
    Holmes RS; Crabtree E; McDonagh MS
    Diabetes Obes Metab; 2019 Apr; 21(4):984-992. PubMed ID: 30552792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
    Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
    Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
    Kabadi UM
    Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.
    Pieber TR; Treichel HC; Hompesch B; Philotheou A; Mordhorst L; Gall MA; Robertson LI
    Diabet Med; 2007 Jun; 24(6):635-42. PubMed ID: 17381500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The comparison of 24-hour urinary sodium, albumin, and protein excretion in chronic kidney disease patients with type 2 diabetes mellitus using insulin detemir or insulin glargine.
    Afsar B
    Clin Drug Investig; 2013 Oct; 33(10):773-8. PubMed ID: 23943142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
    Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
    Renard E; Dubois-Laforgue D; Guerci B;
    Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
    Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
    Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
    Wallace JP; Wallace JL; McFarland MS
    Ann Pharmacother; 2014 Mar; 48(3):361-8. PubMed ID: 24396092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.
    Kato T; Tokubuchi I; Muraishi K; Sato S; Kato T; Hara K; Tanaka K; Kaku H; Tajiri Y; Yamada K
    Diabetes Res Clin Pract; 2010 Dec; 90(3):e64-6. PubMed ID: 20850885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
    Fujii H; Watanabe Y; Ueki A; Ohno A; Kato M; Kondo K; Takamura H; Takesue M; Nishimura H; Matsuda D; Miyakawa T
    Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
    Rautiainen P; Tirkkonen H; Laatikainen T
    Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.